Angioleiomyoma of the sinonasal tract is a rare benign tumor. We report a case of angioleiomyoma of the nasal septum in a 51-year-old woman who complained of frequent epistaxis for 3 months. Surgicalexcision was performed. The excised specimen was 0.7 x 0.5 x 0.4 cm in size, well circumscribed, grayish white, rubbery, and soft. Histological examination showed thick-walled blood vessels and smooth muscle cell proliferation. No nuclear atypia or mitoses were present.
Citations
Citations to this article as recorded by
A Case of Leiomyoma of the Nasal Septum Sung Jae Heo, Jin Hyun Ryu, Jung Soo Kim Journal of Clinical Otolaryngology Head and Neck Surgery.2016; 27(1): 133. CrossRef
A Case of Vascular Leiomyoma in Nasal Cavity: Case Report and Literature Review Sung Won Yoon, Min Joon Park, Eun Mee Han, Jung Hyeob Sohn Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2015; 58(2): 138. CrossRef
A Case of Angioleiomyoma of the Nasal Septum Won Il Park, Ji Sung Shim, Junbum Joo, Ju Eun Cho Journal of Clinical Otolaryngology Head and Neck Surgery.2013; 24(2): 247. CrossRef
Sinonasal Undifferentiated Carcinoma (SNUC) is a very rare, highly aggressive malignant tumor of the nasal cavity and paranasal sinuses. SNUC tends to present with advanced-stage disease, often with intracranial invasion. It requires an aggressive multimodality therapy that includes surgical resection. A cure rate of less than 20% is generally reported in the literature, with most patients dying within 1 year of onset of the disease. Three patients diagnosed as SNUC were treated at the Yeungnam University Medical Center between the years 2000 and 2003 were analyzed retrospectively. All patients presented with the disease very advanced. The three cases were given chemotherapy or chemotherapy with radiotherapy. Two patients died of the disease, surviving only 6 and 11 months following treatment, respectively. We did a follow-up on just the one remaining case with incomplete controlled disease for 27 months. The overall prognosis of SNUC is very poor. We consider that more intensive multimodality therapies are recommended for all patients with SNUC.